Market cap
$155 Mln
Recently Viewed
Clear All$6.22
$0.00 (0.00%)As on 22-Aug-2022 09:30EDT
Market cap
$155 Mln
Revenue (TTM)
$46 Mln
P/E Ratio
47.8
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$4 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
7
Debt to Equity
0
Book Value
$--
EPS
$0.1
Face value
--
Shares outstanding
24,936,900
CFO
$-435.20 Mln
EBITDA
$-568.35 Mln
Net Profit
$-617.62 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
La Jolla Pharmaceutical Co (LJPC)
| 33.8 | 0.5 | 57.9 | 68.1 | -15.5 | -26.1 | 7.6 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
La Jolla Pharmaceutical Co (LJPC)
| 19.8 | -1.3 | -58.3 | -70.5 | 83.6 | -35.1 | 46.3 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood... pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc. Read more
Pres, CEO & Director
Mr. Larry G. Edwards
Pres, CEO & Director
Mr. Larry G. Edwards
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of La Jolla Pharmaceutical Co (LJPC) is $6.22 (NASDAQ) as of 22-Aug-2022 09:30 EDT. La Jolla Pharmaceutical Co (LJPC) has given a return of -15.5% in the last 3 years.
The P/E ratio of La Jolla Pharmaceutical Co (LJPC) is 47.85 times as on 22-Aug-2022.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
8.04
|
-2.37
|
|
2020
|
-2.66
|
-1.19
|
|
2019
|
-0.91
|
-1.90
|
|
2018
|
-1.18
|
6.56
|
|
2017
|
-5.89
|
7.66
|
The 52-week high and low of La Jolla Pharmaceutical Co (LJPC) are Rs -- and Rs -- as of 30-Apr-2026.
La Jolla Pharmaceutical Co (LJPC) has a market capitalisation of $ 155 Mln as on 22-Aug-2022. As per SEBI classification, it is a Small Cap company.
Before investing in La Jolla Pharmaceutical Co (LJPC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.